Internal medicine

Clinical endpoint

Gastroenterology

Surgery

Oncology

Chemotherapy

Progressive disease

Sirolimus

Response Evaluation Criteria in Solid Tumors

Phases of clinical research

Clinical trial

Medicine

Journal of Clinical Oncology

Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor

<i>nab</i>-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors